Avoiding proteasomal processing: The case of EBNA1

Current Topics in Microbiology and Immunology

Volumn 269, Issue , 2002, Pages 23-36

  Dantuma, N P ^a   Sharipo, A ^a   Masucci, M G ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; EPSTEIN BARR VIRUS ANTIGEN; GLYCINE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PROTEASOME; CYSTEINE PROTEINASE; EBV ENCODED NUCLEAR ANTIGEN 1; EBV-ENCODED NUCLEAR ANTIGEN 1; HLA ANTIGEN CLASS 1; MULTIENZYME COMPLEX; UBIQUITIN;

ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ANTIGENICITY; ARTICLE; CYTOTOXIC T LYMPHOCYTE; EFFECTOR CELL; MAJOR HISTOCOMPATIBILITY COMPLEX RESTRICTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN FAMILY; PROTEIN PROCESSING; TANDEM REPEAT; TARGET CELL; VIRUS INFECTION; AMINO ACID SEQUENCE; EPSTEIN BARR VIRUS; GENETICS; IMMUNOLOGY; METABOLISM; NUCLEOTIDE REPEAT; REVIEW; T LYMPHOCYTE; VIROLOGY;

HUMAN HERPESVIRUS 4;

ALANINE; ANTIGEN PRESENTATION; CYSTEINE ENDOPEPTIDASES; EPSTEIN-BARR VIRUS INFECTIONS; EPSTEIN-BARR VIRUS NUCLEAR ANTIGENS; GLYCINE; HERPESVIRUS 4, HUMAN; HISTOCOMPATIBILITY ANTIGENS CLASS I; MULTIENZYME COMPLEXES; PROTEASOME ENDOPEPTIDASE COMPLEX; REPETITIVE SEQUENCES, AMINO ACID; REPETITIVE SEQUENCES, NUCLEIC ACID; T-LYMPHOCYTES; UBIQUITINS;

EID: 0035988018     PISSN: 0070217X     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-642-59421-2_2     Document Type: Article

References (76)

1. Tonsillar memory B cells, latently infected with Epstein-Barr virus, express the restricted pattern of latent genes previously found only in Epstein-Barr virus-associated tumors
2. The expression pattern of Epstein-Barr virus latent genes in vivo is dependent upon the differentiation stage of the infected B cell
3. Ubiquitin-dependent degradation of certain protein substrates in vitro requires the molecular chaperone Hsc70
4. + T cell response: Lessons from the EBV nuclear antigen EBNA1
5. + T cell responses to EBV EBNA1: HLA class I presentation of the (Gly-Ala)-containing protein requires exogenous processing
6. Inhibition of antigen presentation by the glycine/alanine repeat domain is not conserved in simian homologues of Epstein-Barr virus nuclear antigen 1
7. The proteasome
8. E7 protein of human papilloma virus-16 induces degradation of retinoblastoma protein through the ubiquitin-proteasome pathway
9. The base of the proteasome regulatory particle exhibits chaperone-like activity
10. A subpopulation of latently EBV infected normal B-cells resembles Burkitt lymphoma (BL) in expressing EBNA1 but not EBNA2 or LMP1
11. An Epstein-Barr-related herpesvirus from marmoset lymphomas
12. Deubiquitinating enzymes: Their diversity and emerging roles
13. Short-lived green fluorescent proteins for quantification of ubiquitin/proteasome-dependent proteolysis in living cells
14. Inhibition of proteasomal degradation by the Gly-Ala repeat of Epstein-Barr virus is influenced by the length of the repeat and the strength of the degradation signal
15. Antibodies against a synthetic peptide identify the Epstein-Barr virus-determined nuclear antigen
16. The role of repetitive DNA sequences in the size variation of Epstein-Barr virus (EBV) nuclear antigens, and the identification of different EBV isolates using RFLP and PCR analysis
17. Molecular cloning and expression of a multiubiquitin chain binding subunit of the human 26S protease
18. Proteasome subunits X and Y alter peptidase activities in opposite ways to the interferon-γ-induced subunits LMP2 and LMP7
19. γ-interferon and expression of MHC genes regulate peptide hydrolysis by proteasomes
20. Cdc48p interacts with Ufd3p, a WD repeat protein required for ubiquitin-mediated proteolysis in Saccharomyces cerevisiae
21. Cytomegalovirus selectively blocks antigen processing and presentation of its immediate-early gene product
22. A subcomplex of the proteasome regulatory particle required for ubiquitin-conjugate degradation and related to the COP9-signalosome and eIF3
23. Viral vectors for gene therapy: The art of turning infectious agents into vehicles of therapeutics
24. Adenovirus early region 1A protein binds to mammalian SUG1 - A regulatory component of the proteasome
25. A role for the proteasome regulator PA28α in antigen presentation
26. The ubiquitin system
27. Gene therapy in haematology and oncology
28. Newly identified pair of proteasomal subunits regulated reciprocally by interferon γ
29. Hepatitis B virus X protein is both a substrate and a potential inhibitor of the proteasome complex
30. A proteolytic pathway that recognizes ubiquitin as a degradation signal
31. Phosphorylation meets ubiquitination: The control of NF-κB activity
32. Epstein-Barr virus and its replication
33. The sizes of peptides generated from protein by mammalian 26 and 20S proteasomes. Implications for understanding the degradative mechanism and antigen presentation
34. A novel ubiquitination factor, E4, is involved in multiubiquitin chain assembly
35. Structural and functional properties of proteasome activator PA28
36. Substrate targeting in the ubiquitin system
37. Random coil conformation of a Gly/Ala-rich insert in IκB α excludes structural stabilization as the mechanism for protection against proteasomal degradation
38. Inhibition of antigen processing by the internal repeat region of the Epstein-Barr Virus nuclear antigen-1
39. Inhibition of ubiquitin/proteasome-dependent protein degradation by the Gly-Ala repeat domain of the Epstein-Barr virus nuclear antigen 1
40. Inhibition of E6 induced degradation of p53 is not sufficient for stabilization of p53 protein in cervical tumour derived cell lines
41. The Hsc70 co-chaperone CHIP targets immature CFTR for proteasomal degradation
42. A novel form of Epstein-Barr virus latency in normal B cells in vivo
43. Murine cytotoxic T lymphocytes recognize an epitope in an EBNA-1 fragment, but fail to lyse EBNA-1-expressing mouse cells
44. The Epstein-Barr virus EBNA-1 promoter Qp requires an initiator-like element
45. Concurrent chaperone and protease activities of C1pAP and the requirement for the N-terminal C1pA ATP binding site for chaperone activity
46. Mechanisms of MHC class I-restricted antigen processing
47. Trafficking and assembly of MHC molecules: How viruses elude the immune system
48. Lessons from an age-old war
49. PEST sequences and regulation by proteolysis
50. The major substrates for TAP in vivo are derived from newly synthesized proteins
51. Epstein-Barr virus
52. Human cytotoxic T lymphocyte responses to Epstein-Barr virus infection
53. Degradation of cell proteins and the generation of MHC class 1-presented peptides
54. Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules
55. The level of C/EBP protein is critical for cell migration during Drosophila oogenesis and is tightly controlled by regulated degradation
56. Effects on NF-κB1/p105 processing of the interaction between the HTLV-1 transactivator Tax and the proteasome
57. Exclusive expression of Epstein-Barr virus nuclear antigen 1 in Burkitt lymphoma arises from a third promoter, distinct from the promoters used in latently infected lymphocytes
58. Rapid degradation of a large fraction of newly synthesized proteins by proteasomes
59. HIV-1 tat inhibits the 20S proteasome and its 11S regulator-mediated activation
60. Cis-inhibition of proteasomal degradation by viral repeats: Impact of length and amino acid composition
61. A minimal glycine-alanine repeat prevents the interaction of ubiquitinated IκB-α with the proteasome: A new mechanism for selective inhibition of proteolysis
62. Recognition of misfolding proteins by PA700, the regulatory subcomplex of the 26S proteasome
63. HLA-A0201 and HLA-B7 binding peptides in the EBV-encoded EBNA-1, EBNA-2 and BZLF-1 proteins detected in the MHC class I stabilization assay. Low proportion of binding motifs for several HLA class I alleles in EBNA-1
64. Recognition of the polyubiquitin proteolytic signal
65. Cutting edge: Induction of enhanced CTL-dependent protective immunity in vivo by N-end rule targeting of a model tumor antigen
66. The epitopes of influenza nucleoprotein recognized by cytotoxic T lymphocytes can be defined with short synthetic peptides
67. Regulation of the 26S proteasome by adenovirus E1A
68. The multiubiquitin-chain-binding protein Mcb1 is a component of the 26S proteasome in Saccharomyces cerevisiae and plays a nonessential, substrate-specific role in protein turnover
69. The N-end rule: Functions, mysteries, uses
70. The 26S proteasome: A molecular machine designed for controlled proteolysis
71. Novel downstream element upregulates transcription initiated from an Epstein-Barr virus latent promoter
72. Structural basis for the activation of 20S proteasomes by 11S regulators
73. Ubiquitination and deubiquitination: Targeting of proteins for degradation by the proteasome
74. Physical association of ubiquitin ligases and the 26S proteasome
75. A cis-acting element from the Epstein-Barr viral genome that permits stable replication of recombinant plasmids in latently infected cells
76. Structural and functional characterization of interaction between hepatitis B virus X protein and the proteasome complex